The clinical trials nurse’s communication challenge
Oncology clinical trials nurses work in a specialty where the patient’s model of what is happening to them is almost always incomplete in one of three directions. The patient believes they are receiving experimental treatment in exchange for agreeing to unknown risk; they believe the trial is their best or only option, or the reverse, that leaving the trial gives them access to something better; or they believe that every trial procedure — an extra blood draw, a research biopsy, a questionnaire scheduled six months after treatment ends — is a signal about their clinical status. Each of these incomplete models produces a predictable crisis: fear at enrollment when the consent form mentions placebo, the impulse to withdraw when a neighbor appears to have responded to something the trial is not testing, and distress when a research procedure is scheduled without adequate explanation.
The clinical trials nurse occupies a unique position. Unlike the clinical nurse coordinating inpatient care or the oncology clinic nurse explaining treatment recommendations, the clinical trials nurse is simultaneously providing clinical care and representing a research enterprise with its own scientific objectives. The patient is both a patient receiving cancer treatment and a research participant whose adherence to the protocol is essential to the validity of data that will guide future care for thousands of patients who will never be enrolled in this trial. The nurse must keep both dimensions clear — and must do so in Spanish, with patients whose trust is built on whether they feel their clinical interests and their research participation are understood as distinct and genuinely reconcilable.
Three conversations recur in oncology clinical trials nursing with Spanish-speaking patients. The first arises at enrollment or consent review, when the patient reads the word “placebo” and immediately maps it to their cultural understanding of placebo as “nothing.” In most modern Phase III oncology trials, this map is wrong: the placebo is a sham infusion that maintains the blinding of a trial whose control arm is an active, FDA-approved standard therapy. The patient is not at risk of receiving no treatment; the patient is at risk of not receiving the investigational agent in addition to the standard therapy they will receive regardless. The second arises during treatment, when the patient hears about a different treatment — typically through family network or social media — that appears to have worked dramatically for someone with “the same cancer.” In colorectal cancer, this almost always involves checkpoint immunotherapy, and almost always involves a patient with MSS disease hearing about a neighbor with MSI-high disease — a different tumor biology, a different immune microenvironment, and a fundamentally different treatment landscape. The third arises when a protocol procedure is scheduled at a moment when the patient believes no procedure should be necessary, because the scan just showed the tumor is responding.
Clinical trials nurses who can explain these three scenarios precisely — in accurate, accessible Spanish that preserves the integrity of both the clinical relationship and the research relationship — reduce withdrawals driven by misunderstanding, preserve enrollment in trials that benefit the enrolled patient, and build the trust that allows a responding patient to undergo a protocol biopsy with full understanding of what it is and why their sample matters. Three conversations that turn on these distinctions:
Scenario 1: Isabel Torres — 58, retired schoolteacher from Tucson, Arizona, Stage IIIA lung adenocarcinoma enrolled in Phase III pembrolizumab trial
Isabel Torres is fifty-eight years old, a retired elementary school teacher who spent thirty years teaching third grade at a Title I school in South Tucson before retiring two years ago. She presented to her primary care physician six months ago after three months of a cough that she had attributed to seasonal allergies, with one episode of mild hemoptysis that brought her in urgently. Chest CT showed a 3.8-centimeter right upper lobe mass with ipsilateral mediastinal lymphadenopathy. PET-CT confirmed FDG-avid disease in the primary mass (SUV 14.2) and in the right paratracheal and subcarinal nodes, with no evidence of distant metastases. Bronchoscopy with endobronchial ultrasound-guided biopsy returned lung adenocarcinoma. Molecular profiling was negative for EGFR mutations (all common and uncommon), ALK rearrangement, ROS1 rearrangement, KRAS G12C, BRAF V600E, MET exon 14 skipping, RET rearrangement, and NTRK fusion. PD-L1 immunohistochemistry by 22C3 assay: tumor proportion score 52%. Final staging: Stage IIIA (T2bN2M0) by the eighth edition of the TNM classification.
A multidisciplinary tumor board reviewed Isabel’s case. The thoracic oncology team discussed the options: definitive concurrent chemoradiation (carboplatin/paclitaxel with thoracic radiation) followed by durvalumab consolidation per the PACIFIC trial paradigm, which showed significantly improved overall survival compared with chemoradiation alone in unresectable Stage III NSCLC; or enrollment in a Phase III double-blind trial comparing pembrolizumab plus an investigational anti-TIGIT antibody versus pembrolizumab plus placebo in PD-L1 ≥50% metastatic and locally advanced NSCLC, which the tumor board felt was appropriate given that pembrolizumab monotherapy was FDA-approved for PD-L1 ≥50% Stage III and IV NSCLC and that the investigational anti-TIGIT antibody had shown promising Phase II data in PD-L1 high disease.
Isabel met with the thoracic oncologist and the clinical trials coordinator. The oncologist explained the trial and recommended enrollment. He provided the consent form. Isabel took it home to read with her daughter Catalina, who worked as a bilingual dental receptionist. Two days later, Catalina called the clinical trials office: her mother had read the consent document and found a phrase that said participants might receive “placebo.” Isabel was refusing to sign. In her understanding, placebo meant no treatment, and she had a cancer that had not spread but had not been treated yet and was visible on the scan. She was not coming in to receive nothing.
Clinical trials nurse María Ruiz-Castellano called Isabel directly. Isabel answered and was composed but clear: “¿Cómo es posible que el estudio me diga que puedo recibir un placebo? Yo tengo cáncer. El tumor está en el escáner. No entiendo cómo el médico me puede ofrecer la posibilidad de recibir nada cuando tengo una enfermedad que necesita tratamiento ahora.” (How is it possible that the study tells me I may receive a placebo? I have cancer. The tumor is on the scan. I do not understand how the doctor can offer me the possibility of receiving nothing when I have a disease that needs treatment now.)
María recognized the concern immediately. It was the most common misreading of a randomized trial consent form — and it was a misreading that, if uncorrected, would lead Isabel to refuse enrollment in a trial where she would receive an FDA-approved cancer treatment in either arm.
“Voy a explicarle exactamente cómo funciona este estudio y qué significa el placebo en este contexto específico,” María said. “Porque el placebo en este estudio no significa no recibir tratamiento. Y quiero que entienda eso con exactitud antes de tomar cualquier decisión.” (I am going to explain exactly how this study works and what placebo means in this specific context. Because the placebo in this study does not mean receiving no treatment. And I want you to understand that precisely before making any decision.)
María began with the structure of the trial. The study had two arms. In both arms, the patient received pembrolizumab — an intravenous immunotherapy drug that was FDA-approved for lung cancers like Isabel’s with PD-L1 above 50%. If Isabel were not in this trial at all — if she had simply been treated by her oncologist off-trial — pembrolizumab monotherapy would have been the standard first option for her lung cancer given the PD-L1 score. Both arms of the trial included pembrolizumab. The difference between the arms was the second drug. In the investigational arm, patients received pembrolizumab plus an additional antibody called an anti-TIGIT agent. In the control arm, patients received pembrolizumab plus a placebo infusion. The placebo was not a sugar pill and was not “nothing.” It was a single additional intravenous infusion of normal saline — salt water — given on the same schedule as the anti-TIGIT antibody would be given in the other arm. The placebo existed for one purpose: to make the infusion schedule identical in both arms, so that neither Isabel, nor her oncologist, nor María herself would know which arm she was on.
“El placebo en este estudio es una infusión de suero fisiológico — agua con sal — que se da en el mismo horario que el anticuerpo experimental en el otro grupo,” María explained. “Existe para que el programa de infusiones sea idéntico en los dos grupos y para que el estudio sea a doble ciego — para que ni usted, ni el médico, ni yo sepamos en cuál grupo está. Eso es importante para que los resultados del estudio sean precisos.” (The placebo in this study is an infusion of normal saline — water with salt — given on the same schedule as the experimental antibody in the other group. It exists so that the infusion schedule is identical in both groups and so that the study is double-blind — so that neither you, nor the doctor, nor I know which group you are in. That is important so that the study results are accurate.)
She continued: “En los dos grupos — el del medicamento experimental y el del placebo — usted recibe pembrolizumab. El pembrolizumab es el tratamiento estándar aprobado por la FDA para su tipo de cáncer de pulmón con su marcador PD-L1 del 52 porciento. Si no estuviera en este estudio, su médico le ofrecería pembrolizumab como primera opción de todos modos. El estudio está probando si agregar el anticuerpo experimental al pembrolizumab estándar mejora los resultados más que el pembrolizumab solo. De cualquier manera que salga la asignación, usted recibe el tratamiento que corresponde a su diagnóstico.” (In both groups — the experimental drug and the placebo — you receive pembrolizumab. Pembrolizumab is the FDA-approved standard treatment for your type of lung cancer with your PD-L1 marker of 52 percent. If you were not in this study, your doctor would offer you pembrolizumab as the first option anyway. The study is testing whether adding the experimental antibody to standard pembrolizumab improves outcomes more than pembrolizumab alone. Whichever way the assignment comes out, you receive the treatment that corresponds to your diagnosis.)
Isabel was quiet. “¿Entonces en el grupo de control — el grupo del placebo — qué exactamente recibo?” (So in the control group — the placebo group — what exactly do I receive?)
“Pembrolizumab más una infusión de suero fisiológico,” María said. “El pembrolizumab es activo — es el medicamento aprobado para su cáncer. La infusión de suero fisiológico no hace nada clínicamente. Está ahí para que el programa de infusiones sea idéntico en los dos grupos.” (Pembrolizumab plus an infusion of normal saline. The pembrolizumab is active — it is the approved drug for your cancer. The normal saline infusion does nothing clinically. It is there so that the infusion schedule is identical in both groups.)
Catalina, who had been listening, asked: “¿Por qué no simplemente le dan a todos el medicamento experimental?” (Why not simply give everyone the experimental drug?)
María explained clinical equipoise. The trial existed because there was genuine scientific uncertainty about whether the anti-TIGIT antibody added benefit on top of pembrolizumab. The Phase II data had been promising — the anti-TIGIT agent had a reasonable scientific rationale, a safety profile that appeared acceptable at the doses being studied, and early signals suggesting improved response rates in PD-L1 high disease. But Phase II data, from smaller studies without randomized comparison arms, had repeatedly led investigators to believe a drug worked when Phase III data showed it did not, or showed it worked but only in a subset defined retrospectively. The Phase III randomized trial, with a control arm that received the current standard, was the mechanism that could answer the question definitively and provide the evidence base for changing the standard of care if the investigational arm performed better. Without a control arm, there was no reliable way to know whether the investigational arm produced better outcomes or whether it only appeared to.
“El estudio existe porque no sabemos todavía si el anticuerpo experimental agrega beneficio al pembrolizumab,” María explained. “Los datos de estudios más pequeños son prometedores, pero estudios prometedores han llevado a medicamentos que, en estudios grandes, resultaron no ayudar — y algunos causaron más daño que beneficio. El grupo de control con pembrolizumab solo existe para que podamos medir la diferencia con precisión. Si el estudio muestra que el anticuerpo experimental ayuda más, ese resultado cambia el tratamiento estándar para futuros pacientes. Si no muestra beneficio, el grupo de control ya recibió el mejor tratamiento disponible.” (The study exists because we do not yet know whether the experimental antibody adds benefit to pembrolizumab. Data from smaller studies is promising, but promising studies have led to drugs that, in large studies, turned out not to help — and some caused more harm than benefit. The control group with pembrolizumab alone exists so that we can measure the difference accurately. If the study shows the experimental antibody helps more, that result changes the standard treatment for future patients. If it does not show benefit, the control group already received the best available treatment.)
Isabel was quiet for a long moment. Then: “Entonces sin importar el grupo, recibo el medicamento aprobado para mi cáncer.” (So regardless of the group, I receive the approved drug for my cancer.)
“Sí,” María said. “En los dos grupos. La asignación al azar decide si también recibe el anticuerpo experimental — que puede ser mejor, o puede no serlo. El pembrolizumab es seguro en los dos grupos.” (Yes. In both groups. The random assignment decides whether you also receive the experimental antibody — which may be better, or may not be. Pembrolizumab is certain in both groups.)
Isabel agreed to come in and sign the consent form.
Scenario 2: Carlos Medina — 63, retired bus driver from El Paso, Texas, KRAS wild-type MSS metastatic colorectal cancer enrolled in Phase II/III bispecific antibody trial
Carlos Medina is sixty-three years old, a retired bus driver who spent thirty-one years with El Paso’s public transit system and coached youth baseball on weekends for seventeen years before his knees required him to stop. He presented to his primary care physician nine months ago with a change in bowel habits and hematochezia that had developed over six weeks. Colonoscopy showed a 4.2-centimeter fungating mass in the sigmoid colon with obstruction. Pathology returned moderately differentiated adenocarcinoma. Staging CT showed hepatic metastases — two lesions in segments V and VI, both less than two centimeters. CEA at presentation was 224 ng/mL. Molecular profiling: KRAS wild-type, NRAS wild-type, BRAF V600E negative, HER2 not amplified. MMR immunohistochemistry: MLH1, MSH2, MSH6, PMS2 all intact (proficient MMR, pMMR). MSI testing by PCR: microsatellite-stable (MSS). Final staging: Stage IV, T3N1M1a.
After left hemicolectomy with primary anastomosis and placement of an implantable venous access device, Carlos was enrolled in a Phase II/III randomized trial comparing a novel EGFR-VEGF bispecific antibody versus standard FOLFIRI (fluorouracil, leucovorin, irinotecan) plus bevacizumab as first-line therapy for KRAS and NRAS wild-type metastatic colorectal cancer. He had completed three cycles without significant toxicity, and his cycle-three CT showed stable hepatic lesions with mild decrease in the larger lesion from 1.9 to 1.6 centimeters, which the investigator reported as stable disease with possible early response.
At the cycle-four pre-treatment clinic visit, Carlos arrived with his son Marcos, a twenty-nine-year-old who worked in logistics. Marcos spoke quickly as soon as clinical trials nurse Sandra Ortega-Vásquez opened the intake: his father’s friend’s neighbor — a man his father’s age, also with colon cancer, also in El Paso — had been treated at a major cancer center in Houston and had received “inmunoterapia” and was now in complete remission. The family had found the neighbor’s social media posts. His son was documenting them on his phone. Carlos wanted to withdraw from the trial to get the immunotherapy.
“Si ese señor tiene cáncer de colon y está en remisión con inmunoterapia, ¿por qué no me ofrecen eso?” Carlos said. “Quiero saber por qué estoy en un estudio de un bispecifico cuando la inmunoterapia claramente funciona para el cáncer de colon.” (If that man has colon cancer and is in remission with immunotherapy, why are they not offering that to me? I want to know why I am in a bispecific antibody study when immunotherapy clearly works for colon cancer.)
Sandra had encountered this conversation before. She recognized the underlying inference — colon cancer is a single category, immunotherapy worked for someone in that category, therefore immunotherapy should work for everyone in that category — and understood that correcting it required making a molecular distinction accessible to a patient who had not been told about MSI status in terms he could use.
“Voy a explicar por qué el cáncer de colon del vecino de su amigo y el cáncer de colon suyo son dos enfermedades diferentes en el nivel molecular — aunque ambos se llaman cáncer de colon,” she said. “Y por qué esa diferencia es exactamente la razón por la que la inmunoterapia que funcionó para él no funciona para su tipo específico.” (I am going to explain why your friend’s neighbor’s colon cancer and your colon cancer are two different diseases at the molecular level — even though both are called colon cancer. And why that difference is exactly the reason the immunotherapy that worked for him does not work for your specific type.)
Sandra began with DNA mismatch repair. Every cell in the body has machinery dedicated to correcting errors that occur when DNA is copied during cell division. Some colon cancers — approximately fifteen percent of all colorectal cancers — develop because one of the genes encoding this mismatch repair machinery has lost function. These tumors are called mismatch-repair deficient, or dMMR, and they are also called MSI-high because the accumulated replication errors produce instability at sequences of repetitive DNA called microsatellites. A dMMR tumor accumulates thousands of somatic mutations that the mismatch repair machinery would normally have corrected. These mutations generate abnormal peptides — neoantigens — that the immune system can recognize as foreign. The tumor is infiltrated with T-cells. The immune checkpoint PD-1 is upregulated on those T-cells as an exhaustion mechanism. This is exactly the biological condition for which PD-1 checkpoint inhibitors like pembrolizumab and nivolumab were designed: releasing PD-1-exhausted T-cells from suppression to attack the antigen-rich tumor. In dMMR/MSI-high colorectal cancer, pembrolizumab produces objective response rates of approximately 43% in previously treated disease (KEYNOTE-158) and is FDA-approved as first-line therapy for dMMR/MSI-high metastatic colorectal cancer based on KEYNOTE-177, where it showed significantly improved progression-free survival over standard chemotherapy.
“Aproximadamente el quince porciento de los cánceres de colon — los que tienen un defecto en la maquinaria de reparación del ADN — acumulan miles de mutaciones que el sistema inmune puede reconocer como extranjeras,” Sandra explained. “Esos tumores tienen muchos linfocitos T dentro del tumor, y la inmunoterapia con anti-PD-1 funciona muy bien porque libera esos linfocitos para atacar el tumor. Eso probablemente es lo que tiene el vecino del amigo de usted.” (Approximately fifteen percent of colon cancers — those with a defect in the DNA repair machinery — accumulate thousands of mutations that the immune system can recognize as foreign. Those tumors have many T-lymphocytes inside the tumor, and anti-PD-1 immunotherapy works very well because it releases those lymphocytes to attack the tumor. That is probably what your friend’s neighbor has.)
She continued: “El suyo no tiene ese defecto. Los resultados de su biopsia muestran que el sistema de reparación del ADN está intacto — eso se llama tumor MSS, microsatellite-stable. Los tumores MSS acumulan muchas menos mutaciones, tienen muchos menos linfocitos T dentro del tumor, y el sistema inmune no puede atacarlos de la misma manera. En los estudios grandes de pembrolizumab en cáncer de colon sin ese defecto — tumores MSS — la tasa de respuesta es menor del cinco porciento. La inmunoterapia que ayudó al vecino de su amigo no funciona en su tipo de tumor, no porque no se haya intentado, sino porque la biología es diferente.” (Yours does not have that defect. Your biopsy results show that the DNA repair system is intact — that is called MSS tumor, microsatellite-stable. MSS tumors accumulate far fewer mutations, have far fewer T-lymphocytes inside the tumor, and the immune system cannot attack them in the same way. In large studies of pembrolizumab in colon cancer without that defect — MSS tumors — the response rate is less than five percent. The immunotherapy that helped your friend’s neighbor does not work in your tumor type, not because it has not been tried, but because the biology is different.)
Marcos looked at his phone. “¿Cómo sabe usted que el cáncer del vecino era diferente al de mi papá?” (How do you know that the neighbor’s cancer was different from my father’s?)
Sandra explained. The fifteen percent of colorectal cancers that are dMMR/MSI-high are the specific population in whom pembrolizumab is approved and produces dramatic responses. When a patient is reported to have had a complete remission with pembrolizumab for colorectal cancer — the kind of response that generates social media posts and is described as miraculous — dMMR/MSI-high disease is the most likely explanation, because the response rate in MSS disease is so low that dramatic remissions from pembrolizumab in MSS colorectal cancer are not what the oncology community reports. Carlos’s MSS status had been confirmed by both PCR-based MSI testing and MMR immunohistochemistry at the time of his biopsy — the two most reliable methods available. There was no ambiguity.
“Las remisiones completas con pembrolizumab que se reportan en cáncer de colon — las que se describen como milagrosas en redes sociales — ocurren en pacientes con el defecto MMR,” Sandra said. “En el cáncer de colon MSS, las tasas de respuesta con pembrolizumab son tan bajas que remisiones como esa no son lo que la comunidad oncológica reporta para ese tipo. Su resultado fue confirmado por dos pruebas diferentes. El vecino del amigo de usted probablemente tiene el defecto MMR. Su papá no lo tiene.” (Complete remissions with pembrolizumab reported in colon cancer — the ones described as miraculous on social media — occur in patients with the MMR defect. In MSS colon cancer, response rates with pembrolizumab are so low that remissions like that are not what the oncology community reports for that type. Your result was confirmed by two different tests. Your friend’s neighbor probably has the MMR defect. Your father does not.)
Carlos was quiet, absorbing this. Then: “¿Y si salgo del estudio? ¿Qué tratamiento recibiría?” (And if I leave the study? What treatment would I receive?)
Sandra answered directly. Withdrawing from the trial was always his right, without penalty or consequence to his care. If he withdrew, his oncologist would offer him standard first-line therapy for KRAS wild-type MSS metastatic colorectal cancer — FOLFIRI plus bevacizumab, which was exactly the control arm of the trial he was currently enrolled in. He would not gain access to immunotherapy by leaving the trial, because pembrolizumab was not approved for MSS colorectal cancer and his oncologist could not prescribe it off-label without insurance coverage, which he would not receive for an unapproved indication. He would receive the same chemotherapy regimen in either case, with the difference that outside the trial he would not have access to the molecular profiling panel, the pharmacokinetic monitoring, or the additional nursing visits that the trial provided at no cost.
“Si usted sale del estudio hoy, su oncólogo le ofrecería FOLFIRI con bevacizumab — exactamente el mismo tratamiento que recibe el grupo de control del estudio,” Sandra said. “No recibiría inmunoterapia, porque pembrolizumab no está aprobado para cáncer de colon MSS y el seguro médico no lo cubriría para ese diagnóstico. Salir del estudio no le acerca a ninguna otra opción — le da el mismo tratamiento que el estudio ya le está ofreciendo en el grupo de control, sin los beneficios adicionales del protocolo.” (If you leave the study today, your oncologist would offer you FOLFIRI with bevacizumab — exactly the same treatment that the study’s control group receives. You would not receive immunotherapy, because pembrolizumab is not approved for MSS colon cancer and medical insurance would not cover it for that diagnosis. Leaving the study does not bring you closer to any other option — it gives you the same treatment the study is already offering you in the control group, without the additional protocol benefits.)
Marcos nodded slowly. Carlos looked at his son and then at Sandra. “Entonces lo que el estudio me da en el grupo de control es lo mismo que obtendría si saliera.” (So what the study gives me in the control group is the same as what I would get if I left.)
“Exactamente,” Sandra said. “Con la posibilidad de que el grupo experimental — el bispecífico — sea mejor. Y con el perfil molecular adicional y las visitas de enfermería del protocolo que no tendría fuera del estudio.” (Exactly. With the possibility that the experimental group — the bispecific — may be better. And with the additional molecular profile and protocol nursing visits that you would not have outside the study.)
Carlos decided to stay enrolled.
Scenario 3: Rebeca Santos — 51, retired hotel manager from Miami, Florida, HER2-positive gastric cancer enrolled in biomarker Phase II trial with protocol biopsies
Rebeca Santos is fifty-one years old, a retired hotel operations manager who spent twenty-two years working at a luxury hotel in Miami Beach, the last six as director of hotel operations before taking early retirement after her diagnosis. She presented to a gastroenterologist eight months ago after three months of epigastric pain, early satiety, and a twelve-pound weight loss. Upper endoscopy showed a circumferential ulcerative lesion at the gastroesophageal junction. Biopsy returned gastric adenocarcinoma. Staging CT showed a 3.1-centimeter GEJ mass with celiac-axis lymphadenopathy and no evidence of peritoneal disease or hepatic metastases. HER2 testing by immunohistochemistry: 3+ (strongly positive). FISH confirmed HER2 amplification with a HER2/CEP17 ratio of 4.8. PD-L1 CPS score 8. Final staging: cT3N2M0 HER2-positive gastric adenocarcinoma at the GEJ (Siewert type III).
Rebeca was enrolled in a biomarker-driven Phase II trial designed to study HER2 heterogeneity and acquired resistance mechanisms in HER2-positive gastric cancer during trastuzumab-based systemic therapy. The trial’s therapeutic arm followed the ToGA regimen (trastuzumab plus XELOX — capecitabine and oxaliplatin) with the addition of pertuzumab, based on the PETRARCA trial signal. The trial required tumor biopsy at three mandatory time points: baseline (before treatment), at cycle three (approximately ten weeks into treatment), and at confirmed radiographic progression. At baseline, Rebeca had undergone endoscopic biopsy and consented to the additional research collection.
Her cycle-three CT was reviewed by the trial investigator and showed the primary lesion had decreased from 3.1 to 2.1 centimeters, with reduction in the size of the celiac-axis lymph nodes from 1.8 centimeters to 0.9 centimeters in the largest node. CEA had decreased from 18.4 to 6.2. The investigator documented a partial response. Rebeca was told the news at her cycle-three clinic visit. She left the appointment relieved and called her sister in Coral Gables from the parking lot.
Two days later, the clinical trials research coordinator called to schedule the cycle-three protocol biopsy — an endoscopy with tissue collection from the primary lesion. Rebeca was confused and then frightened. The scan had just shown the tumor was responding. Why was the research coordinator calling to schedule a biopsy? A biopsy meant something was wrong. If something was wrong, why hadn’t the doctor called directly? She called her daughter Diana, who called the clinical trials office in distress: her mother believed the scan had been misread and the team had found something they were not telling her.
Clinical trials nurse Elena Vargas-Herrero called Rebeca directly. Rebeca was calm but her voice was tight. “El escáner mostró que el tumor estaba respondiendo. El coordinador llama dos días después para pedir una biopsia. Si el tumor está respondiendo, ¿para qué necesitan otra biopsia?” (The scan showed the tumor was responding. The coordinator calls two days later to ask for a biopsy. If the tumor is responding, why do they need another biopsy?)
Elena recognized the fear immediately. The coincidence of timing — a response confirmed by CT followed within forty-eight hours by a call asking for tissue collection — had produced the inference that the response was not the full picture, that the biopsy was diagnostic rather than protocol-driven, and that the clinical team had information it was withholding.
“Voy a explicarle exactamente por qué el coordinador llamó para programar esa biopsia,” Elena said, “y por qué no tiene relación con ningún resultado nuevo de sus estudios.” (I am going to explain exactly why the coordinator called to schedule that biopsy, and why it has no relation to any new finding from your tests.)
Elena began with the design of the trial. The study Rebeca had enrolled in was not simply a treatment trial testing whether trastuzumab plus pertuzumab plus XELOX produced tumor responses — that had already been studied in the clinical trials that preceded this one. This trial was a biomarker study, designed to answer a specific scientific question: how does HER2 expression and HER2 gene copy number change during treatment in patients with HER2-positive gastric cancer who respond? The scientific question arose from a well-documented phenomenon in HER2-positive gastric cancer called HER2 heterogeneity — the tendency of HER2 expression to be spatially non-uniform within the same tumor. In many HER2-positive gastric cancers, some regions of the tumor express HER2 at high levels while other regions, sometimes only millimeters away, express much lower levels or none at all. Under selective pressure from HER2-directed therapy, the HER2-negative subpopulation can be enriched relative to the HER2-positive population, producing what appears on CT as a partial response while a resistant subclone is growing. This is one of the hypothesized mechanisms of acquired resistance to trastuzumab in gastric cancer — and studying it required serial biopsies from the same tumor at different points during treatment.
“Este estudio no está solo midiendo si el tratamiento funciona — eso ya lo sabemos de estudios anteriores,” Elena explained. “Está estudiando cómo cambia el HER2 del tumor durante el tratamiento. En el cáncer gástrico HER2-positivo, la expresión de HER2 a menudo no es uniforme en todo el tumor — algunas áreas expresan mucho HER2, otras muy poco. Bajo la presión del tratamiento anti-HER2, las células que no expresan HER2 pueden crecer más que las que sí expresan. Para estudiar ese fenómeno, el protocolo necesita muestras del tumor en momentos específicos — antes del tratamiento, en el ciclo tres, y si el tumor cambia. Esos momentos estaban planeados desde antes de que usted se inscribiera.” (This study is not only measuring whether the treatment works — that we already know from earlier studies. It is studying how the tumor’s HER2 changes during treatment. In HER2-positive gastric cancer, HER2 expression is often not uniform throughout the tumor — some areas express a lot of HER2, others very little. Under the pressure of anti-HER2 treatment, the cells that do not express HER2 can grow more than those that do. To study that phenomenon, the protocol needs tumor samples at specific time points — before treatment, at cycle three, and if the tumor changes. Those time points were planned before you enrolled.)
Rebeca asked the central question: “¿El resultado de esa biopsia va a aparecer en mi expediente médico? ¿Va a cambiar mi tratamiento?” (Will the result of that biopsy appear in my medical file? Will it change my treatment?)
Elena gave a direct answer. The tissue from the protocol biopsy would go to the trial’s molecular biology laboratory, not to the clinical pathology department. It would not generate a clinical pathology report in Rebeca’s medical record. The research results — the HER2 copy number, the FISH ratio, the protein expression level — were research data collected for the scientific analysis of the trial. They would not appear in Rebeca’s chart and would not trigger a change in her treatment plan unless the trial’s protocol specifically specified that certain findings would be returned to the clinical team as actionable results — and in this trial, they did not. The biopsy was not a diagnostic procedure ordered because a clinician needed to know if the tumor had changed; it was a research procedure ordered because the protocol required it at cycle three, regardless of the CT result.
“La muestra va al laboratorio de biología molecular del estudio, no a patología clínica,” Elena said. “No va a aparecer en su expediente. No va a generar un informe de patología nuevo. No va a cambiar su plan de tratamiento. Es una recolección de datos de investigación que el estudio necesita en el ciclo tres, independientemente de cómo salga el escáner. El escáner que mostró respuesta es una buena noticia clínica separada de lo que la biopsia está midiendo.” (The sample goes to the study’s molecular biology laboratory, not to clinical pathology. It will not appear in your file. It will not generate a new pathology report. It will not change your treatment plan. It is a research data collection that the study needs at cycle three, regardless of how the scan comes out. The scan that showed response is good clinical news separate from what the biopsy is measuring.)
Diana, who had been listening, asked: “¿Por qué mi mamá en este momento específico, cuando está respondiendo?” (Why my mother at this specific moment, when she is responding?)
Elena explained the scientific logic. The trial was designed to study what changes in the tumor between the pre-treatment state and the mid-treatment state in patients who are responding. If the tumor were progressing, the biopsy at cycle three would be scientifically less useful for understanding acquired resistance, because rapid progression might reflect a tumor that never responded rather than one that initially responded and then developed resistance. Rebeca’s partial response was precisely the clinical scenario the trial was designed to study. Her responding tumor — shrinking on CT, with improved lymph nodes and declining CEA — was the sample the investigators needed to understand what happened to HER2 heterogeneity in a tumor that was responding to HER2-directed therapy. Her biopsy was scientifically valuable in a way that only a responding patient’s biopsy could be.
“El estudio quiere saber cómo cambia el HER2 del tumor en los pacientes que responden al tratamiento,” Elena explained. “Si su tumor no estuviera respondiendo, la biopsia nos diría menos sobre ese fenómeno. El hecho de que su tumor está respondiendo es exactamente por qué su muestra es valiosa para el estudio ahora. No estamos biopsiando porque algo esté mal. Estamos biopsiando porque su respuesta es lo que queremos estudiar.” (The study wants to know how the tumor’s HER2 changes in patients who respond to treatment. If your tumor were not responding, the biopsy would tell us less about that phenomenon. The fact that your tumor is responding is exactly why your sample is valuable to the study right now. We are not doing a biopsy because something is wrong. We are doing a biopsy because your response is what we want to study.)
Rebeca was quiet. Then she said: “Entonces la biopsia responde una pregunta científica sobre mi tumor, no una pregunta clínica sobre si estoy bien.” (So the biopsy answers a scientific question about my tumor, not a clinical question about whether I am okay.)
“Exactamente,” Elena said. “La pregunta clínica — si está respondiendo — ya la respondió el escáner. La biopsia es para la pregunta del estudio — cómo está cambiando el HER2 del tumor mientras responde.” (Exactly. The clinical question — whether you are responding — the scan already answered. The biopsy is for the study question — how the tumor’s HER2 is changing while it responds.)
Rebeca agreed to come in for the procedure.
The discipline that connects all three scenarios
What connects Isabel Torres reading “placebo” in a consent form, Carlos Medina wanting to withdraw after his neighbor’s immunotherapy response, and Rebeca Santos receiving a call for a biopsy when her tumor is shrinking is the same fundamental communication challenge: the patient’s model of what is happening is internally coherent but based on information that is missing, incomplete, or applied from one context to another where it does not hold.
Isabel’s model — placebo means no treatment, and she has active cancer that needs treatment — is a perfectly reasonable model applied to any other context in medicine. It is wrong in this specific trial because the control arm is an active, FDA-approved therapy, and the placebo is a sham infusion that preserves the blinding of a trial where both arms receive effective cancer treatment. The nurse’s job is not to dismiss the concern but to replace the model with the actual structure of the specific trial — arm by arm, infusion by infusion — until the patient can see that the word “placebo” in this document does not mean what it would mean in any other context she has encountered it.
Carlos’s inference — colon cancer is a category, immunotherapy worked for someone in that category, therefore immunotherapy should work for him — is logically sound as a general heuristic and is exactly how patients are expected to reason from their experience and their networks. It is wrong because the category “colon cancer” contains at least two biologically distinct populations with fundamentally different immune microenvironments, and the dramatic responses to checkpoint inhibitors that generate social media posts are concentrated almost entirely in the MSI-high fifteen percent, not the MSS eighty-five percent. The nurse’s job is to make the molecular distinction real and specific enough that the patient understands why the neighbor’s experience is not transferable, and why the trial he is enrolled in is actually offering him the same standard care he would receive if he left.
Rebeca’s fear — a biopsy scheduled immediately after a response means the team is worried about something they are not disclosing — is based on a reasonable model of how biopsies work in clinical medicine, where biopsy is almost always ordered because a clinician needs to know whether tissue contains disease. The protocol biopsy does not follow that logic: it is scheduled by a calendar, at a time point determined before enrollment, regardless of the clinical state of the patient. The nurse’s job is to distinguish the two purposes of biopsy — clinical diagnostic versus research biomarker collection — in terms that are specific enough that the patient understands neither what the sample will not do (change her treatment, appear in her chart) nor what it will do (answer a scientific question about the biology of her responding tumor that only her responding tumor can answer).
In each case, the nurse who can deliver the explanation accurately, in accessible Spanish, in a single phone call, prevents a withdrawal driven by misunderstanding, preserves the patient’s enrollment in a trial that is either offering them the current standard of care in both arms or studying biology that may benefit future patients with their cancer, and builds the trust that allows the patient to proceed as an informed participant rather than an anxious subject. The clinical trials nurse who makes this work in Spanish is doing what the consent form alone cannot do: translating the design logic of a research protocol into the terms a patient can use to make a genuine decision.
Key phrases for clinical trials nurses working with Spanish-speaking patients:
- On the placebo at enrollment: “El placebo en este estudio es una infusión de suero fisiológico que hace que el programa de infusiones sea idéntico en los dos grupos. El grupo de control recibe [tratamiento aprobado] más esa infusión de suero. Usted recibe [tratamiento aprobado] independientemente del grupo.” (The placebo in this study is a saline infusion that makes the infusion schedule identical in both groups. The control group receives [approved treatment] plus that saline infusion. You receive [approved treatment] regardless of the group.)
- On randomization: “La asignación al azar existe para que los dos grupos sean comparables en todo excepto el tratamiento que estamos evaluando. Es la única manera de saber con certeza si el medicamento ayuda más.” (Random assignment exists so that the two groups are comparable in everything except the treatment we are evaluating. It is the only way to know with certainty whether the drug helps more.)
- On withdrawal: “Usted puede salir del estudio en cualquier momento sin ningún efecto en su atención médica. Si sale, su oncólogo le ofrecerá el tratamiento estándar para su diagnóstico.” (You can leave the study at any time without any effect on your medical care. If you leave, your oncologist will offer you the standard treatment for your diagnosis.)
- On a protocol biopsy in a responding patient: “Esta biopsia no es porque algo esté mal. Es un paso del protocolo programado desde antes de que usted se inscribiera. La muestra va al laboratorio de investigación, no a su expediente clínico, y no va a cambiar su plan de tratamiento.” (This biopsy is not because something is wrong. It is a protocol step scheduled before you enrolled. The sample goes to the research laboratory, not to your clinical file, and will not change your treatment plan.)